Please Wait
Applying Filters...
menu
    • menu
    European CDMO and Gx manufacturer with 75 years of experience in delivering premium APIs to pharmaceutical partners worldwide.

    Virtual Booth

    Contact Supplier

    Minakem delivers API, HPAPI, steroids & CDMO services for generics with FDA/GMP certification, regulatory know-how & proven success.

    Virtual Booth

    Contact Supplier

    USP reference standards; highly characterized specimens of drug substances, impurities, excipients, degradation products & more.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    Guizhou Utide Biotechnology Co., Ltd. - Specialized GMP manufacturing for next-generation GLP-1 peptide APIs.

    Virtual Booth

    Contact Supplier

    Menu

    Actinium-225

    ACTIVE PHARMA INGREDIENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Gates-Backed Terrapower Sketches Out $450M Radioisotope Facility
    Gates-Backed Terrapower Sketches Out $450M Radioisotope Facility

    18 Mar 2026

    // FIERCE PHARMA

    https://www.fiercepharma.com/pharma/gates-backed-terrapower-isotopes-blueprints-450m-plant-supply-next-wave-radiopharmaceuticals

    FIERCE PHARMA
    18 Mar 2026
    Share Share
    Terrapower Isotopes Announces cGMP Manufacturing Facility
    Terrapower Isotopes Announces cGMP Manufacturing Facility

    17 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/terrapower-isotopes-announces-cgmp-manufacturing-facility-302716027.html

    PR NEWSWIRE
    17 Mar 2026
    Share Share
    Niowave, Novartis Ink Actinium-225 Deal for Cancer Therapy
    Niowave, Novartis Ink Actinium-225 Deal for Cancer Therapy

    11 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/niowave-and-novartis-enter-global-actinium-225-supply-agreement-to-advance-next-generation-cancer-therapies-302684489.html

    PR NEWSWIRE
    11 Feb 2026
    Share Share
    Novartis Cuts 6 Cancer Candidates, Adds 2 to Oncology Strategy
    Novartis Cuts 6 Cancer Candidates, Adds 2 to Oncology Strategy

    05 Feb 2026

    // BIOSPACE

    https://www.biospace.com/business/novartis-cuts-6-early-cancer-candidates-adds-2-to-refine-oncology-strategy

    BIOSPACE
    05 Feb 2026
    Share Share
    NorthStar Confirms Successful Commercial-Scale Ac-225 Production
    NorthStar Confirms Successful Commercial-Scale Ac-225 Production

    06 Jan 2026

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20260106279631/en/NorthStar-Medical-Radioisotopes-Confirms-Successful-Routine-Commercial-scale-Ac-225-Production

    BUSINESSWIRE
    06 Jan 2026
    Share Share
    AtomVie Secures Ac-225 Supply from Ionetix to Advance Radiopharma
    AtomVie Secures Ac-225 Supply from Ionetix to Advance Radiopharma

    18 Dec 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/atomvie-global-radiopharma-secures-a-supply-agreement-with-ionetix-corporation-to-accelerate-ac-225-radiotherapeutics-development-302645520.html

    PR NEWSWIRE
    18 Dec 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.